EUVIMEDEUVIMED entdecken
LeitlinieSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy

Katherine M Robinson iD, Seenae Eum iD, Zeruesenay Desta iD, Rachel F Tyndale iD, Andrea Gaedigk iD, Richard C Crist iD, Cyrine E Haidar iD, Alan L Myers iD, Caroline F Samer iD, Andrew A Somogyi iD, Pablo Zubiaur iD, Otito F Iwuchukwu iD und 5 weitere

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3338 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Katherine M Robinson und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Analgesics, Opioid, Cytochrome P-450 CYP2B6, Genotype, Methadone. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NHGRI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methadone is a mu (μ) opioid receptor agonist used clinically in adults and children to manage opioid use disorder, neonatal abstinence syndrome, and acute and chronic pain. It is typically marketed as a racemic mixture of R ‐ and S ‐enantiomers. R ‐methadone has 30‐to 50‐fold higher analgesic potency than S ‐methadone, and S ‐methadone has a greater adverse effect (prolongation) on the cardiac QTc interval. Methadone undergoes stereoselective metabolism. CYP2B6 is the primary enzyme responsible for catalyzing the metabolism of both enantiomers to the inactive metabolites, S ‐ and R ‐2‐ethylidene‐1,5‐dimethyl‐3,3‐diphenylpyrrolidine ( S ‐ and R ‐EDDP). Genetic variation in the CYP2B6 gene has been investigated in the context of implications for methadone pharmacokinetics, dose, and clinical outcomes. Most CYP2B6 variants result in diminished or loss of CYP2B6 enzyme activity, which can lead to higher plasma methadone concentrations (affecting S‐ more than R‐ methadone). However, the data do not consistently indicate that CYP2B6 ‐based metabolic variability has a clinically significant effect on methadone dose, efficacy, or QTc prolongation. Expert analysis of the published literature does not support a change from standard methadone prescribing based on CYP2B6 genotype (updates at www.cpicpgx.org ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidCytochrome P-450 CYP2B6GenotypeMethadoneOpioid-Related DisordersHumansOpiate Substitution TreatmentPharmacogeneticsPharmacogenomic Variants

Substanzen

Analgesics, OpioidCYP2B6 protein, humanCytochrome P-450 CYP2B6Methadone

Autor:innen und Institutionen

  • Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
  • Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri, USA.
  • Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Pharmacology & Toxicology, and Psychiatry, The Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
  • Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Research Institute, Kansas City, Missouri, USA.
  • School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.

ORCID-Profile: Katherine M Robinson, Seenae Eum, Zeruesenay Desta, Rachel F Tyndale, Andrea Gaedigk, Richard C Crist, Cyrine E Haidar, Alan L Myers, Caroline F Samer, Andrew A Somogyi, Pablo Zubiaur, Otito F Iwuchukwu, Michelle Whirl-Carrillo, Teri E Klein, Kelly E Caudle, Roseann S Donnelly, Evan D Kharasch

Förderung

  • NIGMS NIH HHS
  • NHGRI NIH HHS

Zitieren

APA

Robinson, K. M., Eum, S., Desta, Z., Tyndale, R. F., Gaedigk, A., Crist, R. C., Haidar, C. E., Myers, A. L., Samer, C. F., Somogyi, A. A., Zubiaur, P., Iwuchukwu, O. F., Whirl-Carrillo, M., Klein, T. E., Caudle, K. E., Donnelly, R. S., & Kharasch, E. D. (2024). Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3338

Vancouver

Robinson KM, Eum S, Desta Z, Tyndale RF, Gaedigk A, Crist RC, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3338

BibTeX
@article{Robinson2024,
  author = {Robinson, Katherine M and Eum, Seenae and Desta, Zeruesenay and Tyndale, Rachel F and Gaedigk, Andrea and Crist, Richard C and Haidar, Cyrine E and Myers, Alan L and Samer, Caroline F and Somogyi, Andrew A and Zubiaur, Pablo and Iwuchukwu, Otito F and Whirl-Carrillo, Michelle and Klein, Teri E and Caudle, Kelly E and Donnelly, Roseann S and Kharasch, Evan D},
  title = {Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3338}
}
Kostenlos starten →